Moreover, thymol demonstrated dose-dependent anti-inflammatory effects in an Alzheimer’s disease model, significantly reducing serum and hippocampal levels of IL-1, IL-6, TNF-α, and COX-2, with optimal effects at 80 mg/kg [55]. The gene discussed is PTGS2; the disease is early-onset autosomal dominant Alzheimer disease.